Systematic ReviewResearchMedication SafetyWorkflow

Stopping oxytocin in active labor may reduce hyperstimulation without changing cesarean risk

The Cochrane database of systematic reviews (PubMed)Aug 25, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A Cochrane review found discontinuing intravenous oxytocin in active induced or augmented labor may reduce uterine hyperstimulation, while making little or no difference to cesarean or instrumental birth risk.

What NurseJet pulled from the source

Nine randomized trials involved 4,814 term singleton pregnancies. Discontinuation may make little or no difference to cesarean birth and made little or no difference to instrumental birth. It may reduce uterine hyperstimulation, while the active phase may be about 35 minutes longer; certainty for those two findings was low and very low, respectively.

Why this matters for nurses

Labor nurses titrate ordered oxytocin and continuously integrate contraction patterns, fetal heart rate, and labor progress. The review highlights a possible hyperstimulation benefit from discontinuation but does not establish a single best protocol for every patient.

Bedside takeaway

Stopping oxytocin in active labor may reduce hyperstimulation, but the evidence does not establish one protocol for every patient.

How This Applies in Practice

Use this when: Monitoring a term patient receiving intravenous oxytocin for induction or augmentation during active labor.

On your shift

Verify the current oxytocin order, active-labor criteria, titration plan, and protocol-defined stop or reduction triggers.
Continuously interpret uterine activity and fetal heart rate together and document the response to dose changes.
Escalate tachysystole, abnormal fetal heart rate findings, or other maternal or fetal concerns through the obstetric pathway.

Keep in mind: Discontinuation decisions require individualized assessment. Follow the labor-unit protocol, facility policy, and provider orders.

Key takeaways

The review included nine randomized trials involving 4,814 women in induced or augmented active labor.
Discontinuation may make little or no difference to cesarean birth and did not meaningfully change instrumental birth risk.
Stopping oxytocin may reduce uterine hyperstimulation, although the evidence was low certainty.
Neonatal-unit admission and acidotic cord-gas outcomes showed little or no difference between strategies.

Practice implications

Confirm the ordered oxytocin plan and active-labor criteria, monitor uterine activity and fetal heart rate, and respond to tachysystole or abnormal tracing through the unit pathway. Do not stop or continue the infusion based on this review alone.

Limitations & cautions

Risk of bias varied, 10 potentially eligible studies remained awaiting classification, and certainty ranged from high to low. Evidence for longer active labor was very low certainty, and the review does not define an individualized oxytocin order.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The Cochrane database of systematic reviews (PubMed)

The Cochrane database of systematic reviews (PubMed). Continuation versus discontinuation of intravenous oxytocin in the active phase of labour.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42639841/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)Sep 7, 2026Research Article

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementAI summary · original source linked below

Among 161 adult hospitalizations meeting serum-creatinine criteria for acute kidney injury, 39 cases (24.2%) were undocumented. Length of stay and in-hospital mortality did not differ significantly by documentation status.

Key takeaways

In the 149 hospitalizations with a demonstrable creatinine change, 33 cases (22.1%) were undocumented.
Higher maximal creatinine was associated with lower adjusted odds of underdocumentation.
The study did not test whether a detection or documentation intervention improves care or outcomes.

Why this matters on shift

A smaller creatinine rise may receive less attention even when it meets the study's laboratory definition of acute kidney injury, which can affect how renal risk is communicated across the inpatient team.

Bedside takeaway

Trend ordered renal-function results and communicate clinically important changes through local escalation and documentation workflows.

Nursing implications

Trend ordered renal-function results and communicate clinically important changes through the care team according to local escalation and documentation workflows.

Limitations & cautions

Abstract-only summary. This was a retrospective, single-center study of 161 hospitalizations; urine-output criteria and reliable preadmission creatinine values were unavailable, and the reference creatinine method may affect case classification.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Renal failure (PubMed). Underdocumentation of laboratory-defined acute kidney injury in internal medicine wards: a retrospective cohort study.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of midwifery & women's health (PubMed)Sep 7, 2026Research Article

A retrospective analysis of US natality data found no statistically significant yearly difference in neonatal mortality between freestanding birth centers and hospitals among term, singleton, vertex births without major medical risk factors from 2015 through 2024.

L&D / OB PedsAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Adjusted neonatal-mortality odds for freestanding birth centers fluctuated around 1.0 across the 10-year study period. No individual year showed a statistically significant difference from hospital births, including 2020 and 2021 when birth-center volume increased.

Key takeaways

The analysis was restricted to births meeting selected low-risk criteria.
The study found no evidence that higher birth-center use during the pandemic years increased neonatal mortality.
The observational design cannot establish that birth setting itself caused the mortality pattern.

Why this matters on shift

The findings add national outcome data for counseling and systems planning around freestanding birth-center care for appropriately selected low-risk pregnancies.

Bedside takeaway

Apply local eligibility, surveillance, escalation, and transfer protocols when caring for planned low-risk birth-center patients.

Nursing implications

Keep eligibility, surveillance, escalation, and transfer decisions anchored to local birth-center criteria and maternal-newborn protocols.

Limitations & cautions

Abstract-only summary. The study used retrospective vital-record data, was limited to selected low-risk births, and cannot exclude residual differences between people who delivered in birth centers and hospitals.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of midwifery & women's health (PubMed). Neonatal Mortality Risk Among Births in Freestanding Birth Centers, 2015 to 2024.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

European heart journal (PubMed)Sep 6, 2026Research Article

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPatient EducationAI summary · original source linked below

Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).

Key takeaways

At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Why this matters on shift

The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.

Bedside takeaway

Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.

Nursing implications

Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

One in four laboratory-defined AKI cases went undocumented on medicine wards

Low-risk birth-center births showed no higher neonatal mortality in a 10-year analysis

Targeted vitamin D did not significantly reduce major cardiovascular events after MI